Announces development of a second generation superoxide dismutase (SOD) compound. DDI is also developing a first generation human SOD product and is in Phase II clinicals with bovine SOD for osteoarthritis of the knee.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.